User login

We offer our registered users tailored information, free online courses and exclusive content.

You have an old EXCEMED account ...

Our platform has been renewed. All users registered at any of the old websites are kindly requested to reset their password. Why is this?

... or you lost your password?

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

2014 Asia-Pacific endocrine conference: optimal management of diabetes and thyroid diseases

2014 Asia-Pacific endocrine conference: optimal management of diabetes and thyroid diseases
  • Cardiometabolic
    Endocrinology and metabolism
  • Diabetes
    Thyroid disorder
International conference by Excemed
Saturday, Jun 7 - Sunday, Jun 8 2014
Manila, Philippines



Event format

Registration status


Type 2 diabetes mellitus is a growing epidemic in the Asia-Pacific countries, mainly due to the acquisition of a western life-style and the increasing occurrence of obesity. The complications and comorbidities associated with such conditions are an increasing burden to the healthcare systems and professionals of the region, also because of the lack of standardised guidelines for their care and management appropriate in this setting.

Thyroid disorders are very common in the Asia-Pacific region, the main reason being the endemic iodine deficiency in such population causing goiter and gland dysfunction. Hypothyroidism, thyroid nodules and eventually cancer are common problems for the healthcare professionals of these countries and represent a challenge for the healthcare systems in terms of early diagnosis, standard of treatment and possibly prevention.

EXCEMED is continuing its efforts to spread knowledge about the latest achievements in the field of diabetes and thyroid disorders by organising a dedicated annual meeting in the 2014, tailored to endocrinologists, diabetologists and general practitioners involved in managing the care of these important diseases.

The aims of this live educational conference are to review the most significant achievements of research in this field, and to share the best practice for the clinical management of such diseases in daily practice.

Learning objectives

After attending this live educational conference, learners will have up-todate knowledge about the research and clinical management of diabetes and thyroid disorders, and particularly will be able to:

  • Improve the proper use of oral anti-diabetic agents in different conditions
  • Appraise the insights of complications and comorbidities associated with diabetes for a better management in daily clinical practice
  • Recognise the burden of thyroid disorders from their diagnosis to different therapies
  • Apply international standards for managing conditions such as thyroid disorders in pregnancy and differentiated thyroid cancers

Accreditation details

EXCEMED ( is accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) to  provide  the  following  CME  activity  for  medical  specialists.  The  EACCME  is  an institution  of  the  European  Union  of  Medical  Specialists  (UEMS), The 2014 Asia-Pacific endocrine conference: optimal management of diabetes and thyroid diseases to be held in Manila, Philippines on 7-8 June 2014, is designated  for  a  maximum  of  9  (nine)  hours  of  European  CME  credits  (ECMEC). Each medical specialist should claim only those credits that he/she actually spent in the educational activity. EACCME® credits are recognized by the American Medical Association towards the Physician’s Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, please contact the AMA.



EXCEMED adheres to the principles of the Good CME Practice Group (gCMEp).

Scientific programme

Saturday 7 June 2014



Session I: Managing diabetes and related disorders

Chair: R. Mirasol (Philippines)


Facing the epidemic of “diabesity” in the Asia-Pacific region today

R. Mirasol (Philippines)     View video lecture

Metformin as first line therapy in diabetes: hypoglycaemia and beyond

M. Mafauzy (Malaysia)

Second line therapies in diabetes: from incretins to insulins

N.N.M. Soetedjo (Indonesia)

Tools for improving adherence to treatment in diabetes

I. Tan (Philippines)

Pharmacological management of pre-diabetes: pros and cons


Session II: Complications and comorbidities associated with diabetes

Chair: R. Mirasol (Philippines)


Diabetes and autoimmunity

G. Kahaly (Germany)     View video lecture

CVD in the setting of diabetes: a growing problem in clinical practice

B. Sethi (India)

Pathophysiology of diabetic neuropathy and its possible treatments

R. Mirasol (Philippines)


Session III: From iodine deficiency and goitre to thyroid dysfunction

Chair: G. Kahaly (Germany)


Iodine intake, thyroid function and neurocognitive development: a key relationship

N. Nicodemus (Philippines)

Diagnosis and management of hypothyroidism in its different causes

S.Y. Chia (Republic of Singapore)

Graves' disease: pathophysiology and management

G. Kahaly (Germany)

Sunday 8 June 2014


Session IV: Thyroid disorders in special conditions and thyroid cancer

Chair: P. Vitti (Italy)


Cardiovascular implications of thyroid dysfunctions

G. Kahaly (Germany)

Thyroid disorders in pregnancy: when and how the endocrinologist should intervene

R. Sahay (India)

International guidelines for managing differentiated thyroid cancers

P. Vitti (Italy)


Session V: Workshops with clinical case presentations


Managing gestational diabetes: from diagnosis to insulin therapy

P. Gatbonton (Philippines)

Dissecting the thyroid nodules: from ultrasound to interventions

P. Vitti (Italy)


George J. Kahaly

Professor of Medicine and Endocrinology / Metabolism, Chief of the endocrine outpatient clinic
Dept of Medicine
Gutenberg University Medical Center
Mainz, Germany

Roberto Mirasol

Section of endocrinology, diabetes and metabolism
St Lukes Medical Centre
Quezon City, Philippines


EXCEMED adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programmes awarding continuing education credits must be balanced, independent, objective, and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the programme (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the programme and all programme-related materials neither imply an endorsement nor a recommendation on the part of EXCEMED. All presentations represent solely the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

Su-Ynn Chia declared no potential conflict of interest.

George Kahaly declared no potential conflict of interest.

Mohamed Mafauzy declared no potential conflict of interest.

Roberto Mirasol declared to be member of a company advisory board, board of directors or other similar groups:Merck, Merck Sharpe and Dohme.

Nemencio A. Nicodemus declared receipt of honoraria or consultation fees from Novartis, Merck, Eli Lilly. He declared also to be member of a company advisory board, board of directors or other similar groups: Merck, Astra Zeneca.

Rakesh Sahay declared receipt of honoraria or consultation fees from Sanofi, Novo Nordisk, Eli Lilly, Astra Zeneca, Abbott, BMS.

Bipin Sethi declared no potential conflict of interest.

Nanny N.M. Soetedjo declared no potential conflict of interest.

The following faculty have provided no information regarding significant relationship with commercial supporters and/or discussion of investigational or non-EMEA/FDA approved (off-label) uses of drugs as of 26 May 2014.

Patricia Gatbonton

Iris Thiele Isip Tan

Paolo Vitti